Acetylsalicylic Acid, Diclofenac, and Lornoxicam, but Not Rofecoxib, Affect Platelet CD 62 Expression

Anesthesia and Analgesia

Volumn 98, Issue 4, 2004, Pages 1082-1085

  Blaicher, Alex M ^a,c   Landsteiner, Harald T ^b   Al Falaki, Olga ^b   Zwerina, Jochen ^b   Volf, Ivo ^a   Gruber, Diego ^a   Zimpfer, Michael ^a,b   Hoerauf, Klaus ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DICLOFENAC; LORNOXICAM; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; ROFECOXIB;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE FUNCTION;

EID: 1642420530     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000105866.99259.94     Document Type: Article

References (18)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
2. Vane JR. Biomedicine: back to an aspirin a day? Science 2002;296:474-5.
3. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002;63:817-21.
4. Homoncik M, Malec M, Marsik C, et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol 2003;21:229-31.
5. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40:1509-15.
6. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
7. McCrory CR, Lindahl SG. Cyclooxygenase inhibition for postoperative analgesia. Anesth Analg 2002;95:169-76.
8. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20.
9. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor-pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60.
10. Kenny GN. Potential renal, haematological and allergic adverse effects associated with nonsteroidal anti-inflammatory drugs. Drugs 1992;44:31-6.
11. Riendeau D, Percival MD, Boyce S, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997;121:105-17.
12. Klein T, Nusing RM, Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994;48:1605-10.
13. McEver RP. Role of selectins in leukocyte adhesion to platelets and endothelium. Ann N Y Acad Sci 1994;714:185-9.
14. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000;343:1520-8.
15. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
16. Faraday N. Platelets, perioperative hemostasis, and anesthesia. Anesthesiology 2002;96:1042-3.
17. Dogan IV, Ovali E, Eti Z, et al. The in vitro effects of isoflurane, sevoflurane, and propofol on platelet aggregation. Anesth Analg 1999;88:432-6.
18. de Rossi LW, Horn NA, Hecker KE, et al. Effect of halothane and isoflurane on binding of ADP- and TRAP-6-activated platelets to leukocytes in whole blood. Anesthesiology 2002;96:117-24.